LT3778897T - Imunoonkolitinės terapijos - Google Patents

Imunoonkolitinės terapijos

Info

Publication number
LT3778897T
LT3778897T LTEP20189155.3T LT20189155T LT3778897T LT 3778897 T LT3778897 T LT 3778897T LT 20189155 T LT20189155 T LT 20189155T LT 3778897 T LT3778897 T LT 3778897T
Authority
LT
Lithuania
Prior art keywords
immuno
oncolytic therapies
oncolytic
therapies
Prior art date
Application number
LTEP20189155.3T
Other languages
English (en)
Inventor
Stephen Howard Thorne
Original Assignee
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Pittsburgh - Of The Commonwealth System Of Higher Education filed Critical University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Publication of LT3778897T publication Critical patent/LT3778897T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
LTEP20189155.3T 2013-08-22 2014-08-22 Imunoonkolitinės terapijos LT3778897T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361868978P 2013-08-22 2013-08-22

Publications (1)

Publication Number Publication Date
LT3778897T true LT3778897T (lt) 2024-02-12

Family

ID=52484194

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP20189155.3T LT3778897T (lt) 2013-08-22 2014-08-22 Imunoonkolitinės terapijos

Country Status (26)

Country Link
US (2) US11478518B2 (lt)
EP (3) EP3036329B1 (lt)
JP (3) JP6912199B2 (lt)
KR (1) KR102389240B1 (lt)
CN (1) CN105658795B (lt)
AU (1) AU2014308648B2 (lt)
CA (3) CA3213715A1 (lt)
DK (2) DK3036329T3 (lt)
EA (1) EA037582B1 (lt)
ES (2) ES2971528T3 (lt)
FI (1) FI3778897T3 (lt)
HK (1) HK1223402A1 (lt)
HR (1) HRP20240078T1 (lt)
IL (1) IL243996A0 (lt)
LT (1) LT3778897T (lt)
MD (2) MD4624C1 (lt)
MX (1) MX2016002257A (lt)
NZ (1) NZ716825A (lt)
PE (1) PE20160673A1 (lt)
PH (1) PH12016500329A1 (lt)
PL (1) PL3778897T3 (lt)
PT (1) PT3778897T (lt)
RS (1) RS65104B1 (lt)
SG (1) SG11201600960PA (lt)
SI (1) SI3778897T1 (lt)
WO (1) WO2015027163A1 (lt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3213715A1 (en) 2013-08-22 2015-02-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immuno-oncolytic thereapies
EP3261669B1 (en) 2015-02-25 2022-08-03 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
WO2017014296A1 (ja) * 2015-07-22 2017-01-26 国立大学法人鳥取大学 ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子
JP6895968B2 (ja) * 2015-09-08 2021-06-30 シルラジェン インコーポレイテッド サイトカインおよびカルボキシルエステラーゼを発現する腫瘍溶解性改変ワクシニアウイルス、および、その使用方法
CA3004530A1 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
SG11201807051VA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
CN109152827B (zh) 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
CA3057579A1 (en) * 2016-03-25 2017-09-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Synthetically enveloped virus
EP3254692A1 (en) * 2016-06-10 2017-12-13 Ceva Sante Animale Multivalent recombinant spv
CN109890965A (zh) * 2016-07-19 2019-06-14 匹兹堡大学联邦***高等教育 靶向stat3的溶瘤病毒
JP2019528753A (ja) * 2016-09-21 2019-10-17 スティーブン エイチ． ソーン， 高移動度グループｂｏｘｉ突然変異体
GB201616365D0 (en) 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
CN110520438A (zh) * 2017-02-03 2019-11-29 匹兹堡大学联邦***高等教育 溶瘤病毒疗法
WO2018165161A1 (en) * 2017-03-06 2018-09-13 Novartis Ag Methods and compositions for determining the potency of a therapeutic cellular composition
KR20190137911A (ko) * 2017-04-21 2019-12-11 신라젠(주) 항암 백시니아 바이러스와 관문 저해제 병용 요법
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
US20210093684A1 (en) * 2017-10-31 2021-04-01 KaliVir Immunotherapeutics LLC Platform oncolytic vector for systemic delivery
EP3717000A1 (en) 2017-12-01 2020-10-07 Gerd Sutter Immuno-modulated replication-efficient vaccinia virus strain
AU2019205036A1 (en) * 2018-01-05 2020-08-20 Ottawa Hospital Research Institute Modified orthopoxvirus vectors
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
CA3106983A1 (en) * 2018-07-20 2020-01-23 Ansun Biopharma, Inc. Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
WO2020124274A1 (en) * 2018-12-21 2020-06-25 Ottawa Hospital Research Institute Modified orthopoxvirus vectors
CN113661236A (zh) * 2019-01-07 2021-11-16 卡利威尔免疫治疗公司 治疗癌症的方法
US11529402B2 (en) * 2019-01-14 2022-12-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
US11685904B2 (en) 2019-02-14 2023-06-27 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
JP2022552377A (ja) * 2019-10-16 2022-12-15 カリヴィル イムノセラピューティクス， インコーポレイテッド 改変細胞外エンベロープウイルス
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CA3163805A1 (en) * 2019-12-12 2021-06-17 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
EP4087591A1 (en) * 2020-01-09 2022-11-16 Pfizer Inc. Recombinant vaccinia virus
IL308018A (en) * 2021-04-30 2023-12-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for different MHC expression
AU2022303363A1 (en) * 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023106839A1 (ko) * 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912421A (zh) * 2002-08-12 2010-12-15 杰能斯有限公司 涉及痘病毒和癌的方法及组合物
WO2007023725A1 (ja) * 2005-08-25 2007-03-01 Yokohama City University 遺伝子ワクチン
WO2007030668A2 (en) 2005-09-07 2007-03-15 Jennerex Biotherapeutics Ulc Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8980246B2 (en) * 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
AU2012244210B2 (en) * 2005-09-07 2014-10-02 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
WO2009124044A2 (en) * 2008-03-31 2009-10-08 University Of Florida Research Foundation, Inc. Tumor growth inhibition via conditioning of tumor microenvironment
CA2774144C (en) 2009-09-14 2018-02-13 Jennerex, Inc. Oncolytic vaccinia virus combination cancer therapy
US20130202639A1 (en) 2010-03-25 2013-08-08 Konstantin G. Kousoulas Synthetic Herpes Simplex Viruses for Treatment of Cancers
EA201301173A1 (ru) * 2011-04-15 2015-08-31 Дженелюкс Корпорейшн Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
WO2014047350A1 (en) * 2012-09-20 2014-03-27 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
CA3213715A1 (en) 2013-08-22 2015-02-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immuno-oncolytic thereapies

Also Published As

Publication number Publication date
JP6912199B2 (ja) 2021-08-04
MD4748C1 (ro) 2021-09-30
CA2921041A1 (en) 2015-02-26
US20160235793A1 (en) 2016-08-18
PT3778897T (pt) 2024-02-01
EP3778897A1 (en) 2021-02-17
CN105658795A (zh) 2016-06-08
RS65104B1 (sr) 2024-02-29
DK3778897T3 (da) 2024-01-29
ES2971528T3 (es) 2024-06-05
MD4748B1 (ro) 2021-02-28
PE20160673A1 (es) 2016-07-21
US11478518B2 (en) 2022-10-25
IL243996A0 (en) 2016-04-21
US20230008089A1 (en) 2023-01-12
JP2022062171A (ja) 2022-04-19
HRP20240078T1 (hr) 2024-03-29
DK3036329T3 (da) 2021-01-11
EP3036329A4 (en) 2017-08-02
CN105658795B (zh) 2020-07-03
ES2847305T3 (es) 2021-08-02
JP2019205451A (ja) 2019-12-05
JP2016527920A (ja) 2016-09-15
CA3213683A1 (en) 2015-02-26
JP7333431B2 (ja) 2023-08-24
SG11201600960PA (en) 2016-03-30
KR20160044529A (ko) 2016-04-25
EA037582B1 (ru) 2021-04-16
SI3778897T1 (sl) 2024-03-29
HK1223402A1 (zh) 2017-07-28
JP7021154B2 (ja) 2022-02-16
AU2014308648A1 (en) 2016-03-03
EP3036329B1 (en) 2020-10-07
PL3778897T3 (pl) 2024-04-02
EA201690444A1 (ru) 2016-08-31
WO2015027163A9 (en) 2016-04-14
EP4324918A3 (en) 2024-04-24
PH12016500329A1 (en) 2016-05-02
FI3778897T3 (fi) 2024-01-25
MD4624B1 (ro) 2019-03-31
CA2921041C (en) 2023-10-31
MD20160027A2 (ro) 2016-08-31
MD20180086A2 (ro) 2019-03-31
MX2016002257A (es) 2016-11-08
WO2015027163A1 (en) 2015-02-26
EP4324918A2 (en) 2024-02-21
CA3213715A1 (en) 2015-02-26
AU2014308648B2 (en) 2020-11-12
NZ716825A (en) 2022-02-25
EP3778897B1 (en) 2023-12-20
EP3036329A1 (en) 2016-06-29
KR102389240B1 (ko) 2022-04-20
MD4624C1 (ro) 2019-10-31

Similar Documents

Publication Publication Date Title
HK1223402A1 (zh) 免疫溶瘤療法
DK3689865T3 (en) Hidtil ukendte aminopyrimidinderivater
DK3088517T3 (en) Humant anti-il-33-neutraliserende monoklonalt antistof
DK3736291T3 (en) Anti-FCRH5-antistoffer
DK3354246T3 (en) Udstyrsmonteringssystem
DK3077519T3 (en) Cmv-vacciner
EP3000028A4 (en) AUTOMATIC ADDING TO AN AGENDA
EP2957205A4 (en) HAND DRYER
DK3470074T3 (en) Probiotika
EP2970310A4 (en) 5-Bromo-indirubins
EP2853297A4 (en) kendama
AU353576S (en) Stamphousing
DK3056208T3 (en) Immunpotentiator
DK2979701T3 (en) Antitumormiddel indbefattende irinotecanhydrochloridhydrat
EP3014557A4 (en) TELEPHONE ON FILE
GB201300001D0 (en) Envirep - environment replicater
AU4899P (en) Herbie53 Iresine herbstii
AU4953P (en) Flogazora Gazania rigens
AU4977P (en) Harrosy Gaura lindheimeri
AU353329S (en) Kettlebell
AU353325S (en) Kettlebell
AU353326S (en) Kettlebell
AU353327S (en) Kettlebell
AU353328S (en) Kettlebell
AU353331S (en) Kettlebell